Norstella’s 2026 Pipeline-to-Patient Productivity Index (P3i) shows pharma R&D getting slower and more expensive. Fewer candidates clear Phase I, and the median journey from Phase I to approval now runs 9.3 years. What does this mean for your launch timing planning process?
This report follows two oncology examples from the industry benchmark to the competitor view, covering speed of innovation and development risk. Each uses a four-steps process to enables CI teams to drill down, trend key competitors, assess strategic choice versus operational advantage, and tighten forecasting assumptions.
The report also investigates what a thinning early pipeline can signal about a competitor’s future launches and how company-level Phase I data separates a therapy area signal from portfolio-wide discipline.
The report covers:
- Headline P3i findings on pipeline creation, development timelines and Phase I success
- How oncology timelines and Phase I success compare with the industry picture
- Named-competitor examples showing where speed and attrition diverge, down to phase level
- How to tell whether a competitor’s pace reflects strategic choice or operational advantage
- Six focus areas for effective competitor timeline projections, including how to benchmark your own company
